Evaxion Biotech A/S (EVAX)
NASDAQ (CM) NASDAQ (CM) Primary 
Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Nelson Cox - Lake Street Capital Markets, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Evaxion Business Update and Third Quarter 2025 Financial Results.
Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript
Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDT Company Participants Benjamin Wolthers Conference Call Participants Adnan Muhammad Khattak Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Presentation Benjamin Wolthers Welcome to this webinar sharing the 2-year readout from our Evaxion Phase II study in advanced melanoma.
Evaxion A/S - Special Call
Evaxion A/S - Special Call Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Kevin DeGeeter Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Birgitte Rono - Interim CEO & Chief Scientific Officer Thomas Frederik Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Operator Hello, and welcome to Evaxion's Second Quarter 2025 Conference Call. [Operator Instructions] I would now like to turn the conference over to Birgitte Rono, Interim CEO and CSO.
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to the Evaxion First Quarter 2025 Conference Call and Webcast.
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas Schmidt - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Swayampakula Ramakanth - HCW Operator Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast.
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads Kronborg - Vice President, Investor Relations & Communication Conference Call Participants Li Chen - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Chong Liu - Ladenburg Operator Good day and thank you for standing by.
Here's Why Evaxion Biotecch (EVAX) Is a Great 'Buy the Bottom' Stock Now
Evaxion Biotecch (EVAX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
